Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 15/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30355813 | 1.00 | POLB (0.41) | POLBS1PR1S1PR3PIK3CDPIK3CA | |
| SCHEMBL23558484 | 0.82 | POLB (0.44) | POLBS1PR1S1PR3PIK3CDPIK3CA | |
| SCHEMBL30355750 | 0.82 | PIK3CD (0.35) | S1PR1S1PR3PIK3CDPIK3CAPIK3CB | |
| SCHEMBL23523813 | 0.82 | PIK3CD (0.35) | S1PR1S1PR3PIK3CDPIK3CAPIK3CB | |
| SCHEMBL23523975 | 0.82 | POLB (0.44) | POLBS1PR1S1PR3KCNH2RXFP1 | |
| SCHEMBL30355506 | 0.82 | POLB (0.44) | POLBS1PR1S1PR3KCNH2RXFP1 | |
| SCHEMBL30355729 | 0.81 | S1PR1 (0.38) | POLBS1PR1S1PR3PIK3CDPIK3CA | |
| SCHEMBL23524192 | 0.81 | S1PR1 (0.38) | POLBS1PR1S1PR3PIK3CDPIK3CA | |
| SCHEMBL23524431 | 0.74 | MAPT (0.45) | POLBS1PR1S1PR3KCNH2RXFP1 | |
| SCHEMBL2122311 | 0.74 | S1PR1 (0.70) | POLBS1PR1S1PR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | POLB 4432/4885S1PR1 1/4885S1PR3 3/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | POLB 4750/4885S1PR1 1/4885S1PR3 3/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | POLB 4432/4885S1PR1 1/4885S1PR3 3/4885 |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | POLB 4432/4885S1PR1 1/4885S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.